<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03288532</url>
  </required_header>
  <id_info>
    <org_study_id>MRC RE06</org_study_id>
    <nct_id>NCT03288532</nct_id>
  </id_info>
  <brief_title>Renal Adjuvant MultiPle Arm Randomised Trial</brief_title>
  <acronym>RAMPART</acronym>
  <official_title>An International Investigator-led Phase III Multi Arm Multi Stage Multi-centre Randomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kidney Cancer UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: The current global standard of care after nephrectomy for localised RCC therefore&#xD;
      remains active monitoring (i.e., observation by clinical and radiological means). 30-40%&#xD;
      patients with initially localised RCC develop metastatic disease following nephrectomy. Need&#xD;
      for adjuvant therapy is most marked in the high risk population where outcomes are&#xD;
      predictably poor. However, the risk of recurrence in patients who are of intermediate risk of&#xD;
      recurrence is not insignificant. Unfortunately, despite showing efficacy in advanced RCC, the&#xD;
      results in the adjuvant setting, so far, are inconclusive.&#xD;
&#xD;
      AIM: RAMPART is a phase III Multi-Arm Multi-Stage randomised controlled platform trial,&#xD;
      initiated with three arms. The trial is assessing if durvalumab monotherapy or the&#xD;
      combination of durvalumab and tremelimumab can improve Disease Free Survival (DFS) or Overall&#xD;
      Survival (OS) compared to the current global standard-of-care (active monitoring). At the&#xD;
      start of recruitment, patients with Leibovich scores 3 to 11 will be eligible for&#xD;
      randomisation. Accrual of intermediate risk patients (Leibovich scores 3 5) will stop after 3&#xD;
      years or when intermediate risk patients contribute 25% of the total accrual target,&#xD;
      whichever is earlier. Recruitment of patients with Leibovich scores 6 to 11 will continue&#xD;
      until the accrual target is reached.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2034</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multi-Arm Multi-Stage Design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival (DFS): Arm C vs A</measure>
    <time_frame>6.25 years</time_frame>
    <description>Interval from randomisation to first evidence of local recurrence, new primary RCC, distant metastases, or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Free Survival (DFS): Arm B vs A</measure>
    <time_frame>10.54 years</time_frame>
    <description>Interval from randomisation to first evidence of local recurrence, new primary RCC, distant metastases, or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS): Arm C vs A (high risk patients only)</measure>
    <time_frame>13.25 years</time_frame>
    <description>All-cause mortality, the time from randomisation to death from any cause (including RCC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS): Arm B vs A (high risk patients only)</measure>
    <time_frame>20.5 years</time_frame>
    <description>All-cause mortality, the time from randomisation to death from any cause (including RCC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metastasis-free survival (MFS): Arm C vs A</measure>
    <time_frame>6.25 years</time_frame>
    <description>Interval from randomisation to first evidence of metastases or death from RCC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis-free survival (MFS): Arm B vs A</measure>
    <time_frame>10.54 years</time_frame>
    <description>Interval from randomisation to first evidence of metastases or death from RCC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RCC specific survival time: Arm C vs A</measure>
    <time_frame>13.25 years</time_frame>
    <description>Time from randomisation to death from RCC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RCC specific survival time: Arm C vs A</measure>
    <time_frame>20.5 years</time_frame>
    <description>Time from randomisation to death from RCC</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1750</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A (active monitoring)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants randomised to Arm A will be allocated to active monitoring for 1 year, in line with current standard-of-care in resected primary RCC at high or intermediate risk of relapse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (durvalumab monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomised to Arm B will receive durvalumab (1500mg) 4 weekly for 1 year (13 cycles maximum)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (durvalumab + tremelimumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomised to Arm C will receive durvalumab (administered as per arm B, i.e. 13 cycles maximum) and tremelimumab (75mg) on day 1 and week 4 visits (i.e. 2 cycles)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>controlled infusion via an infusion pump into a peripheral or central vein</description>
    <arm_group_label>Arm B (durvalumab monotherapy)</arm_group_label>
    <arm_group_label>Arm C (durvalumab + tremelimumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>controlled infusion via an infusion pump into a peripheral or central vein</description>
    <arm_group_label>Arm C (durvalumab + tremelimumab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically proven RCC (all cell types of RCC are eligible, except for pure&#xD;
             oncocytoma, collecting duct, medullary and transitional cell cancer [TCC]); no&#xD;
             evidence of residual macroscopic disease on post-operative CT scan after resection of&#xD;
             RCC. Patients with treated bilateral synchronous RCCs are eligible.&#xD;
&#xD;
          2. At the start of recruitment patients with Leibovich score 3-11 will be eligible for&#xD;
             randomisation. MRC CTU at UCL will monitor accrual and stop recruiting intermediate&#xD;
             risk patients (Leibovich Score 3-5) after three years or when intermediate risk&#xD;
             patients contribute 25% of the total accrual target, whichever is earlier. Recruitment&#xD;
             of patients with Leibovich Score 6 11 will continue until the accrual target is&#xD;
             reached.&#xD;
&#xD;
          3. Patients should have had surgery at least 28 days but no more than 91 days prior to&#xD;
             their randomisation date.&#xD;
&#xD;
          4. Post-operative scans should be performed within 28 days prior to randomisation.&#xD;
&#xD;
          5. Patients with microscopically positive resection margins after radical nephrectomy at&#xD;
             the nephrectomy bed, renal vein or inferior vena cava are eligible provided the&#xD;
             post-operative CT scan shows no evidence of residual macroscopic disease.&#xD;
&#xD;
          6. WHO Performance Status 0 or 1.&#xD;
&#xD;
          7. Patient has archival FFPE pathology tissue available, and agrees to provide at least&#xD;
             one sample (FFPE tumour block from nephrectomy, or a minimum of 10 unstained slides),&#xD;
             as well as a baseline EDTA blood sample for future translational research).&#xD;
&#xD;
          8. Adequate normal organ and marrow function&#xD;
&#xD;
               1. Haemoglobin ≥9.0g/dL (transfusions will be allowed within 2 weeks prior to&#xD;
                  randomisation in order to achieve the entry criteria).&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) ≥1.5 x 109/L (≥1500 per mm3).&#xD;
&#xD;
               3. Platelet count ≥100 x 109 (≥100,000 per mm3).&#xD;
&#xD;
               4. Bilirubin ≤1.5 x ULN (This will not apply to subjects with confirmed Gilbert's&#xD;
                  syndrome (i.e., persistent or recurrent hyperbilirubinemia that is predominantly&#xD;
                  unconjugated in the absence of haemolysis or hepatic pathology), who will be&#xD;
                  allowed only in consultation with their physician).&#xD;
&#xD;
               5. AST/ALT ≤2.5 x ULN.&#xD;
&#xD;
               6. Calculated Creatinine Clearance level &gt;40mL/min by Cockcroft Gault formula (using&#xD;
                  actual body weight).&#xD;
&#xD;
          9. 12-lead ECG on which QTcF must be &lt;450 ms. In case of clinically significant ECG&#xD;
             abnormalities, including a QTcF value ≥450 ms, two additional 12-lead ECGs should be&#xD;
             obtained over a brief period (e.g., 30 minutes) to confirm the finding. Patients are&#xD;
             only eligible if a QTcF of &lt;450ms is confirmed&#xD;
&#xD;
         10. Subjects must be ≥18 years of age.&#xD;
&#xD;
         11. Written informed consent obtained from the patient.&#xD;
&#xD;
         12. Both men and women enrolled in this trial must be in agreement with trial policy on&#xD;
             contraception during the treatment phase of the study and 6 months afterwards. Egg&#xD;
             donation, sperm donation and breastfeeding must be avoided.&#xD;
&#xD;
         13. Evidence of post-menopausal status or negative serum HCG pregnancy test for female pre&#xD;
             menopausal patients. Women will be considered post-menopausal if they have been&#xD;
             amenorrhoeic for 12 months without an alternative medical cause. The following age&#xD;
             specific requirements apply:&#xD;
&#xD;
               1. Women &lt;50 years of age will be considered post-menopausal if they have been&#xD;
                  amenorrhoeic for 12 months or more following cessation of exogenous hormonal&#xD;
                  treatments and if they have luteinising hormone and follicle-stimulating hormone&#xD;
                  levels in the post-menopausal range for the institution or underwent surgical&#xD;
                  sterilisation (bilateral oophorectomy or hysterectomy).&#xD;
&#xD;
               2. Women ≥50 years of age will be considered post-menopausal if they have been&#xD;
                  amenorrhoeic for 12 months or more following cessation of all exogenous hormonal&#xD;
                  treatments, had radiation-induced menopause with last menses &gt;1 year ago, had&#xD;
                  chemotherapy induced menopause with last menses &gt;1 year ago, or underwent&#xD;
                  surgical sterilisation (bilateral oophorectomy, bilateral salpingectomy, or&#xD;
                  hysterectomy).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous diagnosis of RCC.&#xD;
&#xD;
          2. Metastatic or macroscopic residual disease.&#xD;
&#xD;
          3. Patients with positive resection margins after partial nephrectomy.&#xD;
&#xD;
          4. Patients with a single pulmonary nodule ≥5mm diameter are not eligible unless the&#xD;
             nodule has had a definite benign diagnosis. Patients with multiple small, less than 5&#xD;
             mm nodules may be eligible if nodules have been shown to be radiologically stable for&#xD;
             at least 8 weeks.&#xD;
&#xD;
          5. Prior anticancer treatment (other than nephrectomy) for RCC.&#xD;
&#xD;
          6. Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the&#xD;
             exception of alopecia, vitiligo, and the laboratory values defined in the inclusion&#xD;
             criteria&#xD;
&#xD;
               1. Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after&#xD;
                  consultation with the Study Physician.&#xD;
&#xD;
               2. Patients with irreversible toxicity not reasonably expected to be exacerbated by&#xD;
                  treatment with durvalumab or tremelimumab may be included only after consultation&#xD;
                  with the Study Physician.&#xD;
&#xD;
          7. History of another primary malignancy except for:&#xD;
&#xD;
               1. Malignancy treated with curative intent and with no known active disease ≥5 years&#xD;
                  before the first dose of IP and of low potential risk for recurrence.&#xD;
&#xD;
               2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease.&#xD;
&#xD;
               3. Adequately treated carcinoma in situ without evidence of disease.&#xD;
&#xD;
          8. History of leptomeningeal carcinomatosis.&#xD;
&#xD;
          9. Concurrent enrolment in another clinical study, unless it is an observational (non&#xD;
             interventional) clinical study or during the follow up period of an interventional&#xD;
             study.&#xD;
&#xD;
         10. Major surgical procedure (as defined by the Investigator) within 28 days prior to the&#xD;
             start of treatment. Local surgery of isolated lesions for palliative intent is&#xD;
             acceptable.&#xD;
&#xD;
         11. Current or prior use of immunosuppressive medication within 14 days before the first&#xD;
             dose of durvalumab or tremelimumab, with the exceptions of intranasal and inhaled&#xD;
             corticosteroids or systemic corticosteroids at physiological doses, which are not to&#xD;
             exceed 10 mg/day of prednisone, or an equivalent corticosteroid.&#xD;
&#xD;
         12. Active or prior documented autoimmune or inflammatory disorders (including&#xD;
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with&#xD;
             the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,&#xD;
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid&#xD;
             arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this&#xD;
             criterion:&#xD;
&#xD;
               1. Patients with vitiligo or alopecia&#xD;
&#xD;
               2. Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on&#xD;
                  hormone replacement&#xD;
&#xD;
               3. Any chronic skin condition that does not require systemic therapy&#xD;
&#xD;
               4. Patients without active disease in the last 5 years may be included but only&#xD;
                  after consultation with the RAMPART Trial Management Team&#xD;
&#xD;
               5. Patients with coeliac disease controlled by diet alone&#xD;
&#xD;
         13. A history of immunodeficiency syndrome. Please consult the MRC CTU at UCL on an&#xD;
             individual basis if there is any uncertainty.&#xD;
&#xD;
         14. History of allogeneic organ transplant.&#xD;
&#xD;
         15. Uncontrolled intercurrent illness including, but not limited to:&#xD;
&#xD;
               1. Ongoing or active infection of any kind (patients who are exhibiting symptoms&#xD;
                  consistent with COVID-19, or who have tested positive, should not be randomised&#xD;
                  into the study until they are asymptomatic and at least 14 days after a positive&#xD;
                  test)&#xD;
&#xD;
               2. Symptomatic congestive heart failure&#xD;
&#xD;
               3. Uncontrolled hypertension&#xD;
&#xD;
               4. Unstable angina pectoris&#xD;
&#xD;
               5. Uncontrolled cardiac arrhythmia&#xD;
&#xD;
               6. Active peptic ulcer disease or gastritis&#xD;
&#xD;
               7. Active bleeding diatheses&#xD;
&#xD;
               8. Psychiatric illness or social situations that would limit compliance with study&#xD;
                  requirements or compromise the ability of the subject to give written informed&#xD;
                  consent.&#xD;
&#xD;
         16. Active infection including&#xD;
&#xD;
               1. Tuberculosis (clinical evaluation that includes clinical history, physical&#xD;
                  examination and radiographic findings, and TB testing in line with local&#xD;
                  practice)&#xD;
&#xD;
               2. Hepatitis B (known positive HBV surface antigen (HBsAg) result). Patients with a&#xD;
                  past or resolved HBV infection (defined as the presence of hepatitis B core&#xD;
                  antibody [anti HBc] and absence of HBsAg) are eligible.&#xD;
&#xD;
               3. Hepatitis C&#xD;
&#xD;
               4. Human immunodeficiency virus (positive HIV 1/2 antibodies). Note: Patients&#xD;
                  positive for hepatitis C (HCV) antibody are eligible only if polymerase chain&#xD;
                  reaction is negative for HCV RNA.&#xD;
&#xD;
         17. Receipt of live attenuated vaccine within 30 days prior to the start of treatment.&#xD;
             Note: Patients, if enrolled, should not receive live vaccine while receiving&#xD;
             investigational medicinal product and up to 30 days after the last dose of&#xD;
             investigational medicinal product.&#xD;
&#xD;
         18. Pregnant or breastfeeding patients.&#xD;
&#xD;
         19. Any condition that, in the opinion of the investigator, would interfere with&#xD;
             evaluation of study treatment or interpretation of patient safety or study results.&#xD;
&#xD;
         20. Known allergy or hypersensitivity to durvalumab or tremelimumab, or any of their&#xD;
             excipients.&#xD;
&#xD;
         21. Previous investigational medicinal product assignment in the present study.&#xD;
&#xD;
         22. Clinically significant pneumonitis or fibrosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Larkin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>RAMPART Trial Management Team</last_name>
    <phone>0044(0)207 670</phone>
    <phone_ext>4683/4743</phone_ext>
    <email>mrcctu.rampart@ucl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gordon Urquhart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ysbyty Gwynedd</name>
      <address>
        <city>Bangor</city>
        <zip>LL57 2PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pasquale Innominato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tom Geldart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amit Bahl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sarah Welsh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Centre</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jim Barber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Broomfield Hospital</name>
      <address>
        <city>Chelmsford</city>
        <zip>CM1 7ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gopalakrishnan Srinivasan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cheltenham General Hospital</name>
      <address>
        <city>Cheltenham</city>
        <zip>GL53 7AN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marios Decatris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colchester General Hospital</name>
      <address>
        <city>Colchester</city>
        <zip>CO4 5JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Muthu Kumar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Coventry &amp; Warwickshire</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yakhub Khan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jahangeer Malik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Balaji Venugopal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diana Princess of Wales Hospital</name>
      <address>
        <city>Grimsby</city>
        <zip>DN33 2BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Iqtedar Muazzam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>Hull</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anthony Maraveyas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Raigmore Hospital</name>
      <address>
        <city>Inverness</city>
        <zip>IV2 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Neil McPhail</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Naveen Vasudev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Guy Faust</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Cancer Centre</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard Griffiths</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tom Powles</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Hospital</name>
      <address>
        <city>London</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anand Sharma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ekaterini Boleti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sarah Rudman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James Larkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Naveed Sarwar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tom Waddell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Poulam Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Protheroe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Glan Clwyd Hospital</name>
      <address>
        <city>Rhyl</city>
        <zip>LL18 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carey MacDonald Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scunthorpe General Hospital</name>
      <address>
        <city>Scunthorpe</city>
        <zip>DN15 7BH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>George Bozas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carmel Pezaro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Tyneside District Hospital</name>
      <address>
        <city>South Shields</city>
        <zip>NE34 0PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ashraf Azzabi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southend University Hospital</name>
      <address>
        <city>Southend-on-Sea</city>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Awais Jalil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunderland Royal Hospital</name>
      <address>
        <city>Sunderland</city>
        <zip>SR4 7TP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ashraf Azzabi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James Larkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Torbay Hospital</name>
      <address>
        <city>Torquay</city>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anna Lydon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 4, 2017</study_first_submitted>
  <study_first_submitted_qc>September 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2017</study_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Cell Carcinoma</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Multi-Arm Multi-Stage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

